SCHEMBL746697

SCHEMBL746697

O=C1N(c2ccc(Cl)nc2)CCC12CCN(S(=O)(=O)c1ccccc1)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.50
ALDH1A1 P00352 7/20 0.47
MAPK1 P28482 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
POLB P06746 2/20 0.46
EGLN1 Q9GZT9 2/20 0.45
CYP3A4 P08684 7/20 0.45
USP2 O75604 5/20 0.45
CYP1A2 P05177 4/20 0.45
CYP2C9 P11712 4/20 0.45
CYP2C19 P33261 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
HSD17B10 Q99714 3/20 0.44
TSHR P16473 2/20 0.44
HPGD P15428 1/20 0.44
CYP2D6 P10635 5/20 0.44
HIF1A Q16665 1/20 0.44
NEK2 P51955 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744394 0.83 ALDH1A1 (0.44) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL745637 0.82 CYP3A4 (0.50) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL22396074 0.81 NEK2 (0.51) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL3751874 0.79 LIPE (0.51) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL3751781 0.78 LIPE (0.68) LIPEMEN1KMT2APOLB
SCHEMBL745772 0.78 LIPE (0.53) LIPEALDH1A1CYP3A4USP2CYP1A2
SCHEMBL23529207 0.77 ROCK2 (0.48) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL745741 0.77 LIPE (0.60) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL3745828 0.76 LIPE (0.48) LIPEALDH1A1MAPK1MEN1KMT2A
SCHEMBL744130 0.75 LIPE (0.77) LIPEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430023-B1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS HOFFMANN LA ROCHE (CH) 2013-12-11 EP claimed
US-8329904-B2 Azacyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2012-12-11 US claimed
US-20100292212-A1 NEW AZACYCLIC DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US claimed
EP-2430023-B1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS HOFFMANN LA ROCHE (CH) 2013-12-11 EP disclosed
US-8329904-B2 Azacyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2012-12-11 US disclosed
US-8329904-B2 Azacyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2012-12-11 US disclosed
US-8329904-B2 Azacyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2012-12-11 US disclosed
EP-2430023-A1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-03-21 EP disclosed
WO-2010130665-A1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 WO disclosed
WO-2010130665-A1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 WO disclosed
US-20100292212-A1 NEW AZACYCLIC DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US disclosed
US-20100292212-A1 NEW AZACYCLIC DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292212-A1 NEW AZACYCLIC DERIVATIVES GPR119, LDLR, LPL LIPE 10/4885ALDH1A1 691/4885MAPK1 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.